Mucin based breast cancer vaccines

Bibliography

• GENDLER S, SPICER A: Epithelial mucin genes. Physiol-ogy (1995) 57:607–634.
   Web of Science ®Google Scholar
• GENDLER S, LANCASTER C, TAYLOR-PAPADIMITRIOU J et al.: Molecular cloning and expression of the human tumour-associated polymorphic epithelial mucin. J. Biol. Chem. (1990) 265:15286–15293.
   PubMed Web of Science ®Google Scholar
• •This paper describes the cloning of the MUC I gene.
   Google Scholar
• SHIMIZU Y, SHAW S: Mucins in the mainstream. Nature(1993) 366:630–631.
   PubMed Web of Science ®Google Scholar
• MULLER S, GOLETZ S, PACKER N et al: Localisation of 0-glycosylation sites on glycopeptide fragments from lactation-associated MUCl. J. Biol. Chem. (1997) 272:24780–24793.
   PubMed Web of Science ®Google Scholar
• CLAUSEN H, BENNETT EP: A family of UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferases con-trol the initiation of mucin type 0-glycosylation. Glyco-biology (1996) 6:635–646.
   PubMed Web of Science ®Google Scholar
• SWALLOW D, GENDLER S, GRIFFITH B et al: The human tumour-associated epithelial mucins are coded for by an expressed hypervariable gene locus PEM. Nature (1987) 328:82–84.
   PubMed Web of Science ®Google Scholar
• BRAGA V, PEMBERTON L, DUHIG T, GENDLER S: Spatial and temporal expression of an epithelial mucin, MUC1, during mouse development. Development (1992) 115:427–437.
   PubMed Web of Science ®Google Scholar
• ZOTTER S, HAGEMAN PC, LOSSNITZER A, MOOI WJ, HIL-GERS J: Tissue and tumor distribution of human poly-morphic epithelial mucin. Cancer Rev. (1988) 11–12:55–101.
   Google Scholar
• •This paper documents the distribution of MUC1 in human tissue and tumour.
   Google Scholar
• HO SB, NICHOLS GA, LYFTOGT C et al: Heterogeneity of mucin gene expression in normal and neoplastic tis-sues. Cancer Res. (1993) 53:641–651.
   PubMed Web of Science ®Google Scholar
• BIECHE I, LIDEREAU R: A gene dosage effect is responsi-ble for high overexpression of the MUC1 gene ob-served in human breast tumours. Cancer Genet. Cytogenet. (1997) 98:75–80.
   PubMedGoogle Scholar
• WESSELING J, VAN DER VALK SW, VOS HL, SONNENBERG A, HILKENS J: Episialin (MUC1) overexpression inhib-its integrin-mediated cell adhesion to extracellular matrix components. J. Cell Biol. (1995) 129:255–265.
   PubMed Web of Science ®Google Scholar
• GRAHAM R, BURCHELL J, TAYLOR-PAPADIMITRIOU J: The polymorphic epithelial mucin:potential as an im-munogen for a cancer vaccine. Cancer Immunol. Imrnu-nother. (1996) 42:71–80.
   PubMed Web of Science ®Google Scholar
• •Summarises the potential for MUC1 vaccines.
   Google Scholar
• HANISCH F-G, UHLENBRUCK G, PETER-KATALINIC J et al.: Structures of neutral 0-linked poly-lactosaminoglycans on human skim milk mucins. J. Biol. Chem. (1989) 264:872–883.
   PubMed Web of Science ®Google Scholar
• HULL SR, BRIGHT A, CARRAWAY KL et al.: Oligosaccha-ride differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carci-noma cell line. Cancer Commun. (1989) 1:261–267.
   PubMedGoogle Scholar
• LLOYD K, BURCHELL J, KUDRYASHOV V, YIN BWT, TAYLOR-PAPADIMITRIOU J: Comparison of 0-linked carbohydrate chains in MUC1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. J. Biol. Chem. (1996) 271:33325–33334.
   PubMed Web of Science ®Google Scholar
• WHITEHOUSE C, BURCHELL J, GSCHMEISSNER et al.: A transfected sialyl transferase which is elevated in breast cancer and localises to the medial trans/Golgi apparatus inhibits the formation of core 2 based 0-glycans. J. Cell Biol. (1997) 137:1229–1241.
   PubMed Web of Science ®Google Scholar
• BROCKHAUSEN I, YANG J, BURCHELL J, WHITEHOUSE C, TAYLOR-PAPADIMITRIOU J: Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast can-cer cells. Eur. j Biochem. (1995) 233:607–617.
   PubMedGoogle Scholar
• DENNIS J, WALLER C, TIMPLE R SCHIRRMACHER V: Sur-face sialic acid residues attachment of metastatic tu-mour cells to collagen and fibronectin. Nature (1982) 300:274–276.
   PubMed Web of Science ®Google Scholar
• ITZKOWITZ SH, BLOOM EJ, KOKAL WA et al: Sialosyl Tn: a novel mucin antigen associated with prognosis in co-lorectal cancer patients. Cancer (1990) 66:1960–1989.
   PubMed Web of Science ®Google Scholar
• CHUN M, TERATA N, KODAMI M et al.: Expression of sialyl-Tn antigen is correlated with survival time of pa-tients with gastric carcinomas. Eur. J. Cancer (1993) 29A:1820–1823.
   PubMed Web of Science ®Google Scholar
• MILES DW, LINEHAN J, SMITH P, FILIPE I: Expression of sialyl-Tn in gastric cancer: correlation with known prognostic factors. Br. J. Cancer (1995) 71:1074–1076.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI H, TERAO T, KAWASHIMA Y: Serum sialyl-Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J. Clin. Onco. (1992) 10:95–101.
   PubMed Web of Science ®Google Scholar
• LONGENECKER BM, REDDISH M, MILES DW, MACLEAN GD: Synthetic tumour-associated sialyl-Tn antigen as an immunotherapeutic cancer vaccine. Vaccine Res. (1993) 2:151–162.
   Google Scholar
• MILES D, HAPPERFIELD L, SMITH P et al.: Expression of sialyl-Tn predicts the utility of adjuvant chemotherapy in node positive breast cancer. Br. J. Cancer (1994) 70:1272–1275.
   PubMed Web of Science ®Google Scholar
• SUTHERLAND R: Cell and environment interactions in tumour microregions: the multicell spheroid model. Science (1988) 240:177–184.
   PubMed Web of Science ®Google Scholar
• MILLER S, CODINGTON J, KLEIN G: Further studies on the relationship between allotransplantability in the presence of the cell surface glycoprotein epiglycanin in the TA3-MM mouse mammary carcinoma ascites cell. j Nat. Cancer Inst. (1982) 68:981–988.
   PubMed Web of Science ®Google Scholar
• BURCHELL J, GRAHAM RA, SHEARER M et al.: The MUC1 gene as an immunogen: use of naked DNA and role of dendritic cells. In: Breast Cancer Advances in Biology and Therapeutics. (1996). Calvo F, Crepin M, Magdelenat H (Eds.) 309–313.
   Google Scholar
• AGRAWAL B, REDDISH MA, KRANTZ MJ, LONGENECKERBM: Does pregnancy immunise against breast cancer. Cancer Res. (1995) 55:2257–2261.
   PubMed Web of Science ®Google Scholar
• JEROME K, BARND D, BENDT K et al.: Cytotoxic T-lymphocytes derived from patients with breast adeno-carcinoma recognize an epitope present on the pro-tein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. (1991) 51:2908–2916.
   PubMed Web of Science ®Google Scholar
• •Describes the isolation of MUC1 specific CTLs, possibly MHC unrestricted.
   Google Scholar
• IOANNIDES C, FISK B, JEROME K et al: Cytotoxic T cells from ovarian malignant tumors can recognize poly-morphic epithelial mucin core peptides. J. Immunol. (1993) 151:3693–3703.
   PubMed Web of Science ®Google Scholar
• BURCHELL J, TAYLOR-PAPADIMITRIOU J, BOSHELL M, GENDLER S, DUHIG T: A short sequence within the amino acid tandem repeat of a cancer associated mu-cin, contains immunodominant epitopes. Int. J. Cancer (1989) 44:691–696.
   PubMed Web of Science ®Google Scholar
• GIRLING A, BARTKOVA J, BURCHELL J et al.: A core pro-tein epitope of the polymorphic epithelial mucin de-tected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int. J. Can-cer (1989) 43:1072–1076.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI T, MAKIGUCHI Y, HINODA Y et al.: Expres-sion of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple mye-loma patient. J. Immunol. (1994) 153:2102–2109.
   PubMed Web of Science ®Google Scholar
• FONTENOT J, TJANDRA N, BU D, HO C, MONTELARO R, FINN O: Biophysical characterization of one-, two-, and three tandem repeats of human mucin (MIX]) protein core. Cancer Res. (1993) 53:5386–5392.
   PubMed Web of Science ®Google Scholar
• TAYLOR-PAPADIMITRIOU J: Report on the First Interna-tional Workshop on Carcinoma-associated Mucins. Int. J. Cancer (1991) 49:1–5.
   PubMed Web of Science ®Google Scholar
• ••This paper lists the reactivity of antibodies directed toMUC1.
   Google Scholar
• FINN O, JEROME K, HENDERSON R et al:MUC1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev. (1995) 145:61–89.
   PubMed Web of Science ®Google Scholar
• KOTERA Y, FONTENOT J, PECHER G, METZGAR R, FINN O: Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients. Cancer Res.(1994) 54:2856–2860.
   PubMed Web of Science ®Google Scholar
• GOUREVITCH M, VON MENSDORFF-POUILLY S, LITVI-NOV S et al.: Polymorphic epithelial mucin (MUC1)-containing circulating immune complexes in carci-noma patients. Br. J. Cancer (1995) 72:934–938.
   PubMed Web of Science ®Google Scholar
• VON MENSDORFF-POUILLY S, GOUREVITCH M, KENE-MANS P et al: Humoral immune responses to polymor-phic epithelial mucin (Mud-1) in patients with benign and malignant breast tumours. Eur. J. Cancer (1996) 32A:1325–1331.
   PubMed Web of Science ®Google Scholar
• LALANI E-N, BERDICHEVSKY F, BOSHELL M etal.: Expres-sion of the gene encoding for a human mucin in mouse mammary tumor cells can affect their immuno-genicity. J. of Biol. Chem. (1991) 266:15420–15426.
   Google Scholar
• DING L, LALANI E-N, REDDISH M et al.: Immunogenicity of synthetic peptides related to the core peptide se-quence encoded by the human MUC1 mucin gene: ef-fect of immunisation on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol. and Immunother. (1993) 36:9–17.
   PubMed Web of Science ®Google Scholar
• GRAHAM R, STEWART L, PEAT N, BEVERLEY P, TAYLOR-PAPADIMITRIOU J: MUC1-based immunogens for tu-mour therapy: development of murine model systems. Tumour Targeting (1995) 1:211–221.
   Google Scholar
• GONG J, CHEN D, KASHIWABA M et al: Reversal of toler-ance to human MUC1 antigen in MUC1 transgenic mice immunised with fusions of dendritic and carcinoma cells. Proc. Nati Acad. Sci. USA (1998) 95:6279–6283.
   PubMed Web of Science ®Google Scholar
• •Highlights the importance of dendritic cells/co-stimulatory signals in overcoming tolerance.
   Google Scholar
• SMITH M, BURCHELL JM, GRAHAM R, COHEN E, TAYLOR-PAPADIMITRIOU J: Expression of B7.1 in a MUC1-expressing mouse mammary epithelial tumour cell line overcomes tolerance, but does not induce auto-immunity in MUC1 transgenic mice. J. Immunol (Sub-mitted).
   Google Scholar
• JEROME K, DOMENECH N, FINN O: Tumor-specific cyto-toxic T cell clones from patients with breast and pan-creatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J. Immunol. (1993) 151:1564–1570.
   Google Scholar
• PECHER G, FINN O: Induction of cellular immunity in chimpanzees to human tumor-associated antigen mu-cin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells. Proc. Nat. Acad. of Sci. USA (1996) 93:1699–1704.
   PubMed Web of Science ®Google Scholar
• HENDERSON R, NIMGOANKAR M, WATKINS S et al: Hu-man dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen (MUC-1). Cancer Res. (1996) 56:3763–3770.
   PubMed Web of Science ®Google Scholar
• SAMUEL J, BUDZYNSKI WA, REDDISH MA et al: Immuno-genicity and antitumour activity of a liposomal MUC1 peptide-based vaccine. Int. J. Cancer (1998) 75:295–302.
   PubMed Web of Science ®Google Scholar
• APOSTOLOPOULOS V, XING P-X, MCKENZIE I: Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic anti-gens. Cancer Res. (1994) 54:5186–5193.
   PubMed Web of Science ®Google Scholar
• XING P-X, MICHAEL M, APOSTOLOPOULOS V et al: Phase I study of synthetic MUC1 peptides in breast cancer. Int. J. Oncolog. (1995) 6:1283–1289.
   PubMed Web of Science ®Google Scholar
• APOSTOLOPOULOS V, PIETERSZ G, LOVELAND B, SAN-DRIN M, MCKENZIE I: Oxidative/reductive conjugation of mannan to antigen selects for Thl or Th2 immune responses. Proc. Natl. Acad. Sci. USA (1995) 92:10128–10132.
   PubMed Web of Science ®Google Scholar
• KARANIKAS V, HWANG LA, PEARSON J et al.: Antibodyand T cell responses of patients with adenocarcinoma immunised with mannan-MUC1 fusion protein. J. Clin. Invest. (1997) 100:2738–2792.
   Google Scholar
• APOSTOLOPOULOS V, OSINSKI C, MCKENZIE IFC: MUC1cross-reactive Ga16(1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nature Med. (1998) 4:315–320.
   PubMed Web of Science ®Google Scholar
• GOYDOS J, ELDER E, WHITESIDE T, FINN O, LOTZE M: A Phase I trial of a synthetic mucin peptide vaccine. In-duction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. (1996) 63:298–304.
   Google Scholar
• REDDISH MA, MACLEAN GD, KOGANTY RR et al.: Anti-MUC1 class I restricted CTLs in metastatic breast can-cer patients immunised with a synthetic MUC1 pep-tide. Int. J. Cancer (1998)76:817–823.
   PubMed Web of Science ®Google Scholar
• APOSTOLOPOULOS V, KARANIKAS V, HAURUM JS, MCKENZIE IFC: Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J. Immunol. (1997) 159:5211–5218.
   PubMed Web of Science ®Google Scholar
• HIRD V, MARAVEYAS A, SNOOK D et al.: Adjuvant ther-apy of ovarian cancer with radioactive monoclonal an-tibody. Br. J. Cancer (1993) 68:403–406.
   PubMed Web of Science ®Google Scholar
• GRAHAM RA, BURCHELL JM, BEVERLEY P, TAYLOR-PAPADIMITRIOU J: Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1 expressing syngeneic mouse tumour cells. Int. J. Cancer (1996) 65:664–670.
   PubMed Web of Science ®Google Scholar
• •Describes the use of naked cDNA for MUC1 in an animal model.
   Google Scholar
• HAREVEUNI M, GAUTIER C KIENY M-P et al: Vaccination against tumour cells expressing breast cancer epithe-lial tumour antigens. Proc. Nat. Acad. of Sci. USA (1990) 87:9498–9502.
   PubMed Web of Science ®Google Scholar
• ACRES R, HAREUVENI M, BALLOUL J, KIENY M: Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumours bearing the MUC1 antigen. J. Imm. (1993) 14:136–143.
   Google Scholar
• BALLOUL J, ACRES R, GEIST M et al.: Recombinant MUC1 vaccinia virus: a potential vector for immunotherapy of breast cancer. Cell. Mol. Biol. (1994) 40:49–59.
   PubMed Web of Science ®Google Scholar
• SCHOLL S, ACRES B, SCHATZ C et al.: The polymorphic epithelial mucin (MUC1): A phase I clinical trial testing the tolerance and immunogenicity of a vaccinia virus-MUC1-112 construct in breast cancer. Breast Cancer Res. Treat. (1997) 67. (Abstract 268).
   Google Scholar
• FUNG P, MADEJ M, KOGANTY K, LONGENECKER B: Ac-tive specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumour-associated glycoconjugate. Cancer Research (1990) 50:4308–4314.
   PubMed Web of Science ®Google Scholar
• SINGHAL A, FOHN M.& HAKOMORI S-I: Induction of a-N-Acetylgalactosamine-O-serine/ Threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Research (1991) 51:1406–1411.
   Google Scholar
• MACLEAN GD, REDDISH MA, KOGANTY RR, LONGE-NECKER BM: Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J. Immu-noth. (1996) 19:59–68.
   PubMed Web of Science ®Google Scholar
• FUNG P, LONGENECKER B Specific immunosuppres- sive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine adenocarcinoma (TA3-HA). Can-cer Research (1991) 51:1170–1176.
   PubMed Web of Science ®Google Scholar
• MACLEAN G, MILES D, RUBENS R, REDDISH M & LONGE- NECKER B: Enhancing the effect of THERATOPE STn-KLH cancer vaccine patients with metastatic breast cancer by pre-treatment with low-dose intravenous cyclophosphamide. J. Immunoth. (1996) 19:309–316.
   PubMed Web of Science ®Google Scholar
• ••This paper demonstrates that antibody response to syntheticsialyl-Tn can be augmented by low dose cyclophosphamide.
   Google Scholar
• ZHANG SL, WALBERG LA, OGATA S et al.: Immune seraand monoclonal antibodies define 2 configurations for the sialyl-tn tumour-antigen. Cancer Research (1995) 55:3364–3368.
   PubMed Web of Science ®Google Scholar
• ADLURI S, HELLING F, OGATA S et al: Immunogenicityof synthetic TF-KLH (keyhole limpet hemocyanin) and STN-KLH conjugates in colorectal carcinoma patients. Cancer Immunol. Immunoth. (1995) 41:185–192.
   PubMed Web of Science ®Google Scholar
• DICKLER M, GILEWSKI T, RAGUPATHI G et al.: Vaccina-tion of high risk breast cancer patients with no evi-dence of disease with sialyl Tn cluster - keyhole limpet hemocyanin conjugate plus QS-21. Breast Cancer Res Treat. (1997) 46:68A.
   Google Scholar
• WHITESIDE T, MIESCHER S, HURLIMANN J et al.: Separa-tion, phenotyping and limiting dilution analysis of T lymphocytes infiltrating human solid tumors. Interna-tional Journal of Cancer (1986) 37:803–811.
   PubMed Web of Science ®Google Scholar
• WEI W-Z, HEPPNER G: Breast Cancer Immunology. Can-cer Treatment and Research (1996) 83:395–410.
   PubMedGoogle Scholar
• HEO D, WHITESIDE T, JOHNSON J, CHEN K, BARNES E,HERBERMANN R: Long-term interleukin-2 dependent growth and cytotoxicity of human tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck. Cancer Research (1987) 47:6353–6362.
   PubMed Web of Science ®Google Scholar
• VENETSANAKOS E, BECKMAN I, BRADLEY J & SKINNER J: High incidence of interleukin 10 mRNA but not inter-leukin 2 mRNA detected in human breast tumours. Br. J. Cancer (1997) 75:1826–1830.
   PubMed Web of Science ®Google Scholar
• COVENTRY B, WEEKS S, HECKFORD sincerely et al.: Lack of IL-2 cytokine expression despite IL-2 messenger mRNA transcription in tumor-infiltrating lympho-cytes in primary breast carcinoma: selective expres-sion of early activation markers. J. Immunol. (1996) 156:3486–3492.
   PubMed Web of Science ®Google Scholar
• SCHONDORF T, ENGEL H, LINDEMANN C et al: Cellularcharacteristics of peripheral blood lymphocytes and tumour-infiltrating lymphocytes in patients with gy-naecological tumours. Cancer Immunol. Immunoth. (1997) 44:88–96.
   PubMed Web of Science ®Google Scholar
• BECKER J, CZERNY C, BROCKER E: Maintenance ofclonal anergy by endogenously produced IL-10. Int. Im-munol. (1994) 6:1605–1612.
   PubMed Web of Science ®Google Scholar
• BEISSERT S, HOSOI J, GRABBE S, ASAHINA A, GRANSTEINR: IL-10 inhibits tumor antigen presentation by epider-mal antigen-presenting cells. J. Immunol. (1995) 154:1280–1286.
   PubMed Web of Science ®Google Scholar
• JAKOB U, BUCHNER J: Assisting spontaneity: the role of hsp90 and small Hsps as molecular chaperones. TIBS (1994) 19:205–211.
   PubMed Web of Science ®Google Scholar
• JATTELA M, WISSING D: Heat-shock proteins protect cells from monocyte cytotoxicity: mechanism of self-protection. J. Exp. Med. (1993) 177:231–236.
   PubMed Web of Science ®Google Scholar
• TOES R, BLOM R, OFFRINGA R, KAST W, MELIEF C: Func-tional deletion of tumor-specific CTLs induced by pep-tide vaccination can lead to the inability to reject tumours. J. Immunol. (1996) 156:3911–3918.
   PubMed Web of Science ®Google Scholar
• FERRONE S, MARINCOLA F: Loss of HLA class I antigens by melanoma cells: molecular mechanisms, func-tional significance and clinical relevance. Immunology Today (1995) 16:487–494.
   PubMedGoogle Scholar
• RESTIFO N, ESQUIVEL F, KAWAKAMI Y: Identification of human cancers deficient in antigen processing. J. Exp. Medicine (1993) 177:265–272.
   PubMed Web of Science ®Google Scholar
• HAYWARD JL, CARBONE PP, HEUSON J-C: Assessment of response to therapy in advanced breast cancer. Eur. J. Cancer (1977) 13:89–94.
   Web of Science ®Google Scholar
• RIETHMULLER G, SCHNEIDER-GALDICKE E, SCHLIMOK G et al: Randomised trial of monoclonal antibody for ad-juvant therapy of resected Dukes' C colorectal carci-noma. Lancet (1994) 343:1177–1183.
   PubMed Web of Science ®Google Scholar